Rapidly growing prevalence of neurological and immunodeficiency disorders are triggering promising avenues in the global plasma protein therapeutics market. Plasma protein therapeutics has emerged as the most popular choice in the treatment of immunodeficiency disorders.
Besides, growing usage of protein therapeutics as a drug formulation agent is likely to spur growth of the global plasma protein therapeutics market.
Usage as Drug Formulation Agent to Stimulate Avenues
Plasma protein therapeutics also finds its usage as a drug formulation agent. The application is supported by emerging protein-engineering technologies. Proteins are known to possess excellent therapeutic potential against many syndromes and diseases. Recombinant technologies have created different protein drugs, which are now readily available as therapeutics at reasonable prices for the treatment of various chronic diseases. This is opening new avenues in the plasma protein therapeutics market.
Therapeutic proteins are increasingly gaining prominence as they have proven to be efficacious in the treatment of many potentially fatal diseases such as cancer, heart disorders, and diabetes. Plasma protein therapeutics have also shown promise in treating and managing immunodeficiency disorders.
Request Brochure @
According to the findings of the British Society of Immunology, nearly 6 million people live with a primary immunodeficiency disorders (PID) worldwide, but around 70% to 90% of them are undiagnosed. Though the numbers of people affected by PID are relatively small, the risk of severe complications and the specialist nature of their care add up to a substantial cost burden for their treatment. A case in point is deferred diagnosis of severe combined immune deficiencies (SCID) in infants which can lead to treatment costs of over US$1million per patient. The plasma protein therapeutics market is expected to prosper on the back of these factors.
Immunoglobulins have an important role to play in the immune system of a body. The use of immunoglobulins in the treatment of PID has risen in recent times, which is likely to bolster market growth. Growing use of human albumins in the treatment of blood loss, shocks, and burns is likely to spell growth for global plasma protein therapeutics market in the next five years.
This post was originally published on Industry Updates Daily